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Abstract
Objectives
To determine the long-term effects of in utero progesterone exposure in twin children.
Methods
This study evaluated the health and developmental outcomes of all surviving children born to
mothers who participated in a double-blind, placebo-controlled trial of progesterone given for
the prevention of preterm birth in twin pregnancies (STOPPIT, ISRCTN35782581). Follow-
up was performed via record linkage and two parent-completed validated questionnaires, the
Child Development Inventory and theHealth Utilities Index.
Results
Record linkage was successfully performed on at least one record in 759/781 (97%) children
eligible for follow-up. There were no differences between progesterone-exposed and place-
bo-exposed twins with respect to incidence of death, congenital anomalies and hospitalisa-
tion, nor on routine national child health assessments. Questionnaire responses were
received for 324/738 (44%) children. The mean age at questionnaire follow-up was 55.5
months. Delay in at least one developmental domain on theChild Development Inventory
was observed in 107/324 (33%) children, with no evidence of difference between progester-
one-exposed and placebo-exposed twins. There was no evidence of difference between the
progesterone and placebo groups in global health status assessed using the Health Utilities
Index: 89% of children were rated as having ‘excellent’ health and a further 8% as having
‘very good’ health.
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Conclusions
In this cohort of twin children there was no evidence of a detrimental or beneficial impact on
health and developmental outcomes at three to six years of age due to in utero exposure
to progesterone.
Introduction
Preterm birth, defined as birth prior to 37 weeks’ estimated gestation, is a leading cause of peri-
natal mortality and short-term and long-term morbidity. Twin pregnancies contribute dispro-
portionately to preterm birth.
Progesterone, administered either as intramuscular 17 α-hydroxyprogesterone caproate or
vaginal progesterone, has been demonstrated to reduce the rate of preterm birth in women
with high-risk singleton pregnancies [1–7]. In contrast, we and others have shown that neither
progesterone nor 17 α-hydroxyprogesterone caproate prevents preterm birth in multiple preg-
nancies [8–13]. Use of progesterone for prevention of preterm birth in women with a previous
preterm birth and/or with a short cervix is becoming widespread [14]. In 2011, the USA Food
and Drug Administration approved use of 17 α-hydroxyprogesterone caproate for the preven-
tion of preterm birth in women at risk because of previous spontaneous preterm birth [15].
Previous studies have demonstrated that agents given to pregnant women with the aim of
improving pregnancy outcomes can have unexpected effects on children which may not be ap-
parent at birth but harmful long-term [16]. Hence, long-term follow-up data on children ex-
posed to progesterone are needed.
There is emerging but limited evidence on the long-term effects of in utero exposure to pro-
gesterone when given for the prevention of preterm birth. Follow-up of 274 singleton children,
born to mothers participating in a randomised placebo-controlled trial of 17 α-hydroxyproges-
terone caproate in high-risk singleton pregnancies, demonstrated no difference in health status,
physical examination, or mean score on the Ages and Stages Questionnaire at four years of age
despite prolongation of pregnancy [17]. Follow-up of 991 children born to mothers with twin
pregnancies enrolled in the PREDICT randomised control trial comparing progesterone with
placebo revealed no difference in mean score on the Ages and Stages Questionnaire at six
months and at 18 months of age. Progesterone had no effect on duration of pregnancy in the
PREDICT trial [12].
The aim of our study was to determine the potential adverse and/or beneficial effects of pro-
phylactic in utero progesterone on health and developmental outcomes of children at three to
six years of age. We evaluated a cohort of twin pregnancies in which progesterone had no effect
on short-term (obstetric and neonatal) outcomes, thus allowing any direct effects of progester-
one to be determined.
Methods
This study evaluated outcomes of twin children born to mothers who participated in the
STOPPIT trial, a randomised, double-blind, placebo-controlled trial of progesterone given for
the prevention of preterm birth to women with twin pregnancy.
Briefly, the STOPPIT trial (registered clinical trial, ISRCTN35782581), conducted at nine
National Health Service (NHS) hospitals across the United Kingdom, randomised women to
receive either progesterone gel or placebo gel daily from 24 weeks’ gestation for an average
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period of ten weeks. In the original trial, outcome assessment was limited to obstetric and neo-
natal outcomes. These results have previously been reported: there were no differences in the
primary outcome of intrauterine death or preterm delivery prior to 34 weeks and 0 days of ges-
tation, nor any differences in neonatal outcomes between the progesterone and placebo groups
[10]. All participating women were informed of the possibility of follow-up of their children
and were given the opportunity to withdraw consent for future contact from the research team
if they wished.
We aimed to include all children born to mothers resident in Scotland who had been re-
cruited to the STOPPIT trial, and for whom routine health data could therefore be accessed
through Information Services Division, NHS Scotland. Given that such routine health data
were available for twins resident in Scotland, mothers who were resident in England at the time
of the trial, and all those who emigrated out of a Scottish Health Board after the birth of their
babies were not eligible for follow-up. Mothers who were lost to follow-up, and those for
whom there were insufficient data for tracing were excluded from follow-up. Mothers who
withdrew consent for questionnaire follow-up and those who had experienced the death of one
or more twins were also excluded.
The personal identifiers of mothers of eligible children were used to identify mothers’ rec-
ords on the Community Health Index (CHI) database and thus obtain their up to date contact
details to enable questionnaire distribution. The CHI database contains a record of all patients
registered with a General Practitioner in Scotland.
The personal identifiers of mothers were also used to identify the CHI numbers of children
via linkage to statutory birth registration records. CHI numbers of children are documented on
all routine health records in Scotland, and hence record linkage enabled follow-up of twins’
outcomes through examination of routine health data. In addition, statutory death registration
records were searched using children’s personal identifiers to identify any additional deaths of
twins for whom the CHI numbers were unknown.
Records for twins with known CHI numbers were identified on the national child health
programme information systems Health Visitor First Visit, Six to Eight Week Check, Primary-1
Screening, Neonatal Hearing Screening and Preschool Vision Screening records. Subsequent to
April 2005, child health programme records included a Health Plan Indicator assigned to indi-
cate a child’s level of need for ongoing support to achieve good health and developmental
outcomes.
Twin records were also identified on the hospital outpatient attendance (Scottish Morbidity
Record 00—SMR00) and inpatient and day case discharge (SMR01) datasets. For all twins with
hospital attendances, primary diagnoses at time of discharge (coded via World Health Organi-
sation International Classification of Disease, 10th edition (ICD-10)[18]) were examined.
Those with outpatient or inpatient entries with diagnoses ICD-10 codes Q00-Q99 (Chapter
XVII: Congenital malformations, deformations and chromosomal abnormalities) were defined
as having a congenital abnormality.
Twins in the progesterone and placebo groups were heterogeneous with respect to age, sex,
and gestational age at birth. Accordingly, measures of height, weight and head circumference
were converted into z-scores (standard deviations) using freely available LMS software [19]
and UK 1990 growth reference data [20].
We selected two validated parent-completed questionnaires, theHealth Utilities Index
(HUI) [21] and the Child Development Inventory (CDI) [22] from available paediatric develop-
mental assessment tools, purchasing licenses for the use and exact reproduction of each ques-
tionnaire. Mothers were invited by letter to participate in questionnaire follow-up. All letters
were accompanied by a demographic data questionnaire, an information sheet and a written
consent form. Where telephone numbers of mothers were available, a courtesy call was made
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to ensure questionnaires had been received. Questionnaires were mailed out in 2011 and again
in 2012. In the unusual event that a mother replied twice, data from the most recent question-
naire were used. Mothers completed and returned all questionnaires and investigators calculat-
ed aggregate scores prior to any unmasking. Thereafter, treatment allocation was revealed to
four mothers at their request.
We compared baseline demographic characteristics including maternal age at randomisa-
tion, household index of multiple deprivation (quintile), gestation and chorionicity, and the
age of the children at the time of questionnaire completion in the responding and non-re-
sponding groups.
We summarised all baseline characteristics and outcomes using means (standard deviation),
medians (25th and 75th centiles) or frequencies and percentages where relevant. Outcomes
were analysed using generalised linear models (linear or logistic regression) where appropriate,
adjusting for the clustering at the level of the mother. For other outcomes, Fisher’s exact test or
a comparison of medians was used. Where possible, all effect sizes have 95% percent confi-
dence intervals. All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, North
Carolina). There was no imputation of missing data and all analyses were as randomised.
Ethics approval was granted by the South East Scotland Research Committee 02 (reference
number 10/S1102/70).
All women recruited to the original STOPPIT trial had been informed of the possibility of
direct and record-based follow-up of their babies prior to providing written informed consent
for participation. At the conclusion of the trial, women were reminded of the intention to com-
plete a follow-up study in a newsletter and were given the opportunity to withdraw consent for
further contact from the research team.
At the time of the follow-up study, Community Health Index Advisory Group (CHIAG)
and Privacy Advisory Committee (PAC) approvals were obtained in order to update contact
details of mothers of children eligible for follow-up, identify CHI numbers of eligible children,
and perform anonymised record linkage of children’s CHI numbers to national child health
records so that health data could be obtained. Parents were contacted and gave additional writ-
ten informed consent for the completion of questionnaires.
Results
Of the 500 women in the original STOPPIT trial, 68 were excluded from attempted record link-
age as they lived in England (and would therefore not have relevant health records in Scotland),
leaving 432 for whom record linkage was attempted. A further six women were lost to follow-
up at the end of the original trial and ten could not be identified on the CHI database. There-
fore, 416 women were potentially eligible to be sent a questionnaire and had current contact
details available. Linkage to the children’s CHI numbers was performed in March 2013. CHI
numbers of one child (in seven women) and both children (in 22 women) could not be identi-
fied, leaving 781 children whose CHI numbers were submitted for linkage to national child
health records at ISD (386 in the progesterone group and 395 in the placebo group). Record
linkage was successfully performed on at least one record in 759/781 (97%) children. The num-
bers of children for whom records were linked in each group are shown in Fig 1.
Stillbirth, neonatal or paediatric death was identified in 26 twins in the study cohort: 15
twins in the progesterone group and 11 twins in the placebo group. Two deaths were identified
as having occurred since the findings of the original STOPPIT trial were reported. Deaths, con-
genital malformations, and health service utilisation were similar in the progesterone and
control groups.
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The rate of congenital malformations, identified using data pertaining to primary diagnoses
in children with hospital attendances, was 4% in both the progesterone and placebo groups
(Table 1).
Fig 1. Flow of twins through record linkage at ISD.
doi:10.1371/journal.pone.0122341.g001
Table 1. Health service use and rate of congenital malformations identified in hospital.
Progesterone Placebo
n/N children (%) n/N children (%) Effect size (95% CI), p-value
Hospital outpatient attendance record (SMR-00)
Number of children with any attendance 246/386 (64) 260/395 (66) 0.91 (0.64–1.28), 0.58
Median number of visits per child* 0 [0, 1] 0 [0, 1] p = 0.65
General hospital inpatient record (SMR-01)
Number of children with any admission 159/386 (41) 165/395 (42) 0.97 (0.71–1.33), 0.87
Median cumulative length of stay per admission (days)* 39 [10, 62] 31 [10, 59] p = 0.26**
Congenital malformations (SMR-01)
Number of children with any congenital malformation 17/386 (4) 17/395 (4) 1.04 (0.49–1.21), 0.92
*Data presented as median [IQR]
**Two-sided p value from Wilcoxon Rank Sum test
doi:10.1371/journal.pone.0122341.t001
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Health service utilisation, including outpatient hospital attendances and inpatient hospitali-
sations, was similar for twins in the progesterone and placebo groups. For those who were hos-
pitalised, the median (interquartile range) cumulative length of stay was 39 (10, 62) days in the
progesterone group and 31 (10, 59) days in the placebo group (p = 0.26).
Child Health Surveillance Programme data revealed no differences in terms of developmen-
tal screening between twins in the progesterone and placebo groups (Table 2). There were no
differences in the incidence of developmental concern raised by the parent at theHealth Visitor
First Visit nor in developmental assessment at the Six to Eight Week Check. Height and weight
Table 2. Child Health Surveillance Programme.
Progesterone Placebo
Health Visitor First Visit (0–10 days of life) n/N children
(%)
n/N children
(%)
Effect size (95% CI), p-value
Parental concern*
Number of children with any concern identiﬁed 53/307 (17) 77/311 (25) 0.65 (0.40–1.07), 0.09
Health Plan Indicator
Core 183/307 (60) 191/311 (61) 0.043†
Additional 21/307 (7) 26/311 (8)
Intensive 23/307 (7) 8/311 (3)
PH4P# or unknown 80/307 (26) 86/311 (28)
6–8 Week Check (6–8 weeks of life)
Developmental assessment**
Number of children with any domains identiﬁed as doubtful/uncertain or
abnormal
8/310 (3) 15/320 (5) 0.55 (0.21–1.46), 0.23
Health Plan Indicator
Core 182/310 (59) 176/320 (55) 0.47†
Additional 48/310 (15) 55/320 (17)
Intensive 10/310 (3) 6/320 (2)
PH4P# or unknown 70/310 (23) 83/320 (26)
Primary 1 Screening (4.5–5.5 years) Mean (SD), n Mean (SD), n Mean difference [95% CI], p-
value
Measurement and growth
Height (cm) 111 (5), 165 112 (5), 189 -0.6 [-2.1, 0.8], 0.41
Weight (kg) 19.4 (3.2), 165 19.7 (2.8), 189 0.2 [-1.0, 1.4], 0.74
BMI 15.6 (2), 165 15.6 (1.5), 189 0.2 [-0.3, 0.4], 0.64
Height centile 42.1 (28), 165 48.5 (28.8), 189 -6.4 [-12.3, -0.4], 0.04
Weight centile 43.5 (29.7), 165 48.6 (29.2), 189 -5.2 [-11.3, 1.0], 0.10
Health Plan Indicator
Core 236/371 (64) 264/388 (68) 0.43†
Additional 50/371 (13) 39/388 (10)
Intensive 3/371 (1) 2/388 (1)
PH4P# or unknown 82/371 (22) 83/388 (21)
* The health visitor records parental concerns relating to the child’s feeding, illness, crying, appearance, weight and sleep.
** The health visitor assesses the following developmental domains: gross motor; hearing and communication; and vision and social awareness.
Development is assessed to be normal; abnormal; doubtful/uncertain; or not assessed/incomplete.
#PH4P (Pre-Hall 4 Programme): The Health for All Children screening and surveillance programme was introduced in Scotland from April 2005. The PH4P
utilises the Health Plan Indicator. Children assessed prior to the introduction of the PH4P at local health care providers were not classiﬁed using
this system
† P-value for chi-square test of association.
doi:10.1371/journal.pone.0122341.t002
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data collected at the Primary-1 Screening demonstrated no evidence that progesterone expo-
sure in utero had an important effect on growth in childhood. Both progesterone and placebo
exposed children were near to but less than the 50th centile for weight and height. Although
height centile was marginally significantly lower in the progesterone group compared with the
placebo group, there were no differences in mean height. Hence, the clinical relevance of the
height centile difference is likely to be limited.
There were no differences in the outcomes of sensory screening between the progesterone
and placebo groups (Table 3).
The flow of participants through the questionnaire arm of the study is shown in Fig 2. After
relevant exclusions, 369 families were sent a questionnaire. A positive response was received
from 167 mothers. Data for the primary outcome (CDI and HUI scores) were obtained from
162 mothers (44% of those mailed questionnaires).
The mean age of children at the time of questionnaire response was 55.5 months. S1 Table
(see Supporting Information) shows the characteristics of the responders in comparison with
the non-responders and those who were not sent a questionnaire. Responders tended to be
older, had less social deprivation, had taken more study medication (progesterone and place-
bo), and their children were born at a higher gestational age. Within the group of responders,
there were no differences in demographic characteristics when those allocated to progesterone
were compared to those allocated to placebo. Additionally, within those who responded, there
were no differences in demographic characteristics evaluated in those whose mothers were
originally in the progesterone group compared with those whose mothers were originally in
the placebo group.
Table 4 shows the proportion of children classified as having borderline or delayed develop-
ment on the CDI. No significant difference in risk of abnormal development was seen between
children who received progesterone and those who received placebo.
Table 5 shows global health status in the progesterone and placebo groups. There were no
differences in the global health rating or the individual multi-attribute health status (HUI
Mark II and HUI Mark III) for children in the progesterone group compared with those in the
placebo group.
The proportion of children in each group with a health utilities index of more than one
(indicating some level of impairment) in each developmental domain is shown in S2 Table.
Again, there were no differences in the individual components of the HUI score between
the groups.
Table 3. Sensory Screening.
Progesterone Placebo
n/N children (%) n/N children (%) Effect size (95% CI), p-value
Neonatal hearing screening *
Either ear fail 41/302 (14) 31/301 (10) 1.38 (0.81–2.35), 0.23
Preschool vision screening **
Either eye fail 70/250 (28) 71/263 (27) 1.04 (0.67–1.64), 0.85
*Screeners record the outcome of the ﬁrst screen of each ear as pass, fail/refer, or not done/incomplete.
**Preschool vision screening includes an assessment of visual acuity and ocular movement. The outcome of screening for each eye is recorded as pass,
refer or ongoing follow-up (both indicating failing screening), or recall (indicating screening could not be satisfactorily completed).
doi:10.1371/journal.pone.0122341.t003
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Discussion
The results of this follow-up evaluation of children exposed in utero to progesterone for the
prevention of preterm birth in women with twin pregnancies suggest that progesterone has no
direct effect on child health and developmental outcomes. These findings complement the
findings of the original STOPPIT trial in which progesterone was found to have no significant
effect on the composite outcome of death or delivery before 34 weeks’ gestation [10].
The use of a cohort of women with twin pregnancies, in which progesterone had no effect
on gestational length, allows the direct effect of progesterone to be determined independent of
any effect of progesterone on preterm birth. Hence, our study provides no significant evidence
that in utero progesterone exposure directly enhances the health of exposed children. This is
perhaps surprising; progesterone has been shown to have anti-inflammatory and neuroprotec-
tive properties in models of adult acquired brain injury, and a direct beneficial effect on neuro-
development is plausible [23]. In our study, the parent reported health status of twin children
was excellent or very good for 98% of children, despite 33% of children having evidence of
some developmental delay. The developmental delay likely relates to prematurity, with 28% of
children having been born before 35 weeks’ gestation.
Fig 2. Flow of participants through questionnaire arm of study.
doi:10.1371/journal.pone.0122341.g002
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The results of this follow-up study additionally provide reassurance that progesterone does
not cause harm to children exposed in utero. No difference was found in the overall rate of con-
genital anomalies in the progesterone and placebo groups. In the absence of an anomaly regis-
ter, detection of congenital anomalies was limited to diagnoses made in children who
presented to hospital. Nevertheless, anomalies that cause hospital admission and early death
are likely to have been well recorded and linked.
Previous studies have suggested that progesterone exposure in early pregnancy might in-
crease the risk of hypospadias in males [24]. In the STOPPIT trial, progesterone therapy was
initiated after 24 weeks’ gestation. Thus, administration occurred after the completion of the
embryological development of the male genitalia at 14 weeks. Current evidence indicates there
is no increase in the risk of hypospadias in males exposed to progesterone after 16 weeks [25].
The results of our follow-up study support this hypothesis.
Table 4. Child Development Inventory score categorisation.
Progesterone Placebo
n/N children (%) n/N children (%) OR (95% CI), p-value
Borderline development 18/140 (13) 39/184 (21) 0.55 (0.26–1.19), 0.13
(25 to <30% below age range)
Delayed development 42/140 (30) 65/184 (35) 0.87 (0.46–1.63), 0.66
(30% below age range)
Borderline/delayed development 60/140 (43) 104/184 (57) 0.67 (0.35–1.28), 0.23
(25% below age range)
The CDI is normed so that a child who performs at the level of a child that is 30% younger than their chronological age is classed as having delayed
development. This equates to a developmental performance 2.0 standard deviations below the mean. Around 2% of children would be expected to be in
this category. A child that performs at a level of a child 25 to <30% younger is between 1.5 and <3.0 SD below the mean for developmental performance
and is classed as having borderline development. Around a further 3% of children would be expected to be in this category. An odds ratio less than one
indicates a beneﬁcial effect of progesterone.
doi:10.1371/journal.pone.0122341.t004
Table 5. Health Utilities Indexmulti-attribute health status and global health rating.
Progesterone Placebo
Mean (SD), n Mean (SD), n Mean difference
[95% CI], p-value
Multi-attribute health status
HUI Mark II 0.96 (0.10), 147 0.96 (0.09), 184 0.00 [-0.03, 0.02], 0.70
HUI Mark III 0.96 (0.12), 147 0.97 (0.07), 184 -0.01 [-0.03, 0.02], 0.57
n/N children (%) n/N children (%) p-value
Global health rating
Excellent 129/147 (88) 166/184 (90) 0.51
Very good 14/147 (10) 14/184 (8)
Good 4/147 (3) 4/184 (2)
The Health Utilities Index includes two complementary systems of classiﬁcation of multi-attribute health status in children. HUI Mark II measures health
status as a function of seven attributes: sensation, ambulation, self-care, cognition, emotion, pain and fertility. The HUI Mark III assesses eight attributes:
vision, hearing, speech, ambulation, dexterity, cognition, emotion and pain. Parental responses to questionnaire items are combined and ascribed a multi-
attribute utility score between 0.00 and 1.00 (where 1.00 describes perfect health), calculated using standard formulas for the HUI Mark II and for the HUI
Mark III. Additionally, parents give a global rating of child health on a 5-point Likert-type scale (excellent, very good, good, fair, poor).
doi:10.1371/journal.pone.0122341.t005
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Other studies have raised concerns regarding behavioural outcomes in children exposed in
utero to progesterone [26]. We reported no significant differences between the progesterone
and placebo groups with respect to social development (reported on the CDI), emotion and
cognition (reported on the HUI).
This follow-up did not include a formal evaluation of intelligence and school performance.
Future linkage to educational records could demonstrate whether the apparently high inci-
dence of some developmental delay has any adverse effects on educational attainment.
Our study extends the duration of follow-up of a twin cohort exposed to progesterone in
utero to a mean age of 55.5 months. To date, limited evidence has been published regarding the
long-term (post neonatal) effects of exposure in utero to vaginal progesterone in twins. Only
one published study has evaluated the effects of vaginal progesterone. The previously published
study had a larger sample size (n = 991), but the duration of postnatal follow-up was 18 months
[12]. The duration of follow-up in our study is comparable with that in a study of intrauterine
exposure to an alternative formulation of progesterone, 17 α-hydroxyprogesterone caproate
[17]. This latter study of 274 singleton children, born to mothers participating in a randomised
placebo-controlled trial of 17 α-hydroxyprogesterone caproate in high-risk singleton pregnan-
cies, demonstrated no difference in child health measures despite prolongation of pregnancy
(Table 6).
Given that the accuracy and reliability of paediatric developmental assessment is improved
over time, the longer-term follow-up in our study is important. The relative neuroplasticity of
the immature brain limits the capacity to ascertain a child’s neurodevelopmental status and
prognosis until the age of at least two years [27]. Moreover, subtle delays are more easily identi-
fied as children become social and are exposed to environments where they are directly
Table 6. Studies examining the long-term effects of prophylactic progesterone exposure in utero on childhood outcomes.
Author,
year
Study
population
Progesterone Gestational
age given
Delivery
<34
weeks
Follow-
up rate
Follow-
up age
Congenital
anomalies
Assessment
tool 1
Progesterone
vs. placebo
Assessment
tool 2
Progesterone
vs. placebo
Northen
et al 2007
USA
Singletons
(prior PTB)
Intramuscular
17 α-OHPC
250 mg/week
16–20
weeks to 36
weeks
RR 0.67
(0.48–
0.93)#
80% Mean 48
months
Genital /
reproductive
(2.1% vs.
1.2%; p = 1.0)
ASQ score
below cut-off on
at least one area
(27.5% vs. 28%;
p = 0.92)
PAI mean score
(Boys: 66.5 vs.
67.3; p = 0.3.
Girls: 32 vs. 33;
p = 0.5)
Rode et al
2011
Austria/
Denmark
(PREDICT)
Twins Vaginal natural
progesterone
200 mg/day
20–24
weeks to 34
weeks
OR 0.80
(0.5–1.2)
79.2%
and
74.8%*
6
months,
18
months
Congenital /
chromosomal
(3.8% vs.
4.0%; OR 1.0,
0.5–1.7)
ASQ mean
score at 6
months of age
(215 vs. 218;
p = 0.45)
ASQ mean score
at 18 months of
age (193 vs. 194;
p = 0.89)
McNamara
et al 2015
United
Kingdom
(STOPPIT)
Twins Vaginal natural
progesterone
90 mg/day
24 to 34
weeks
OR 1.36
(0.89–
2.09)
97%
and
44%**
Mean 55
months
Congenital
(4.0% vs.
4.0%; p = 0.92)
CDI score below
cut-off on at
least one area
(30% vs. 35%;
p = 0.66)
HUI global health
rating‘Excellent’
(88% vs. 90%;
p = 0.51)
PTB = preterm birth. 17 α -OHPC = 17 α -hydroxyprogesterone caproate. RR = relative risk (95% conﬁdence interval). OR = odds ratio (95% conﬁdence
interval).
ASQ = Ages and Stages Questionnaire. PAI = Preschool Activities Inventory. CDI = Child Development Inventory. HUI = Health Utilities Index.
#Delivery <35 weeks’ gestation.
*In the PREDICT study, follow-up was achieved for 79.2% of twins at 6 months of age and 74.8% of twins at 18 months of age.
**In our study, follow-up was achieved for 97% of twins via record linkage of at least one health record and 44% of twins via parental questionnaire.
doi:10.1371/journal.pone.0122341.t006
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compared to peers [28]. This is particularly relevant where parent report is used as the method
of assessment.
The rigour of our findings is enhanced by the use of record linkage, which avoids the selec-
tion bias inherent in questionnaire-based studies. Our ability to trace records on 97% of eligible
children using record linkage demonstrates that in the Scottish population, record linkage is an
economical and effective strategy for follow-up of children of women recruited to clinical trials
in pregnancy. We believe that it is unlikely that lack of linkage to the 3% of missing children
would have altered the overall findings.
Questionnaire data supported data from the record linkage and provided more detail on
specific individual outcomes. However, the success rate of questionnaire follow-up was lower,
with only 44% of eligible parents responding. Nevertheless, the questionnaire data supported
the findings of our record linkage study (where the percentage of women and children followed
up was excellent); exposure in utero to progesterone after 20 weeks’ gestation had no adverse
effects.
The power of our follow-up study was dictated by the original sample of the STOPPIT trial.
Additionally, the effective sample size of the follow-up study was reduced by the non-indepen-
dence of data collected for each twin. Clustering was accounted for with multi-level modelling
in our statistical analysis. If the impact of clustering is ignored, our study had 80% power to de-
tect an absolute increase of 10% in hospital admissions, and 95% power to detect an absolute
increase of 13% in hospital admissions in the progesterone group compared with the placebo
group.
Conclusions
In conclusion, we have found that exposure in utero to progesterone, given in twin pregnancies
for the prevention of preterm birth, has no significant impact on child health and developmen-
tal outcomes at three to six years. We demonstrate that, in the absence of an effect on gestation-
al length, progesterone has no beneficial or adverse effects on childhood development. The
limitations of our study are acknowledged and the strengths asserted.
In women with high-risk singleton pregnancies because of short cervix or preterm delivery,
progesterone administration (vaginal progesterone or intramuscular 17 α-hydroxyprogester-
one caproate respectively) has been shown to reduce the rate of preterm birth. An ongoing ran-
domised trial (OPPTIMUM, ISRCTN14568373) will determine whether vaginal progesterone
administration to women at risk because of either a previous preterm birth or a short cervix is
associated with long-term gains in terms of child health and development.
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